DOSING VIDEO

OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is now approved as a subcutaneous injection
In the 1L Treatment of mUGI Cancer*†
New Follow-Up Data in Checkmate 649
‡Fluoropyrimidine- and platinum-containing chemo.1 §Based on Checkmate 649 5-year follow-up analysis (minimum follow-up 60.1 months). In PD-L1 CPS ≥5, mOS was 14.4 mos (95% CI: 13.1–16.2) with OPDIVO + chemo vs 11.1 mos (95% CI: 10.1–12.1) with chemo alone (HR=0.71; 95% CI: 0.61–0.81). In all comers, mOS was 13.7 mos (95% CI: 12.4–14.5) with OPDIVO + chemo vs 11.6 mos (95% CI: 10.9–12.5) with chemo alone (HR=0.79; 95% CI: 0.71–0.88). At primary analysis (minimum 12.1-month follow-up), mOS in PD-L1 CPS ≥5 was 14.4 mos (95% CI: 13.1–16.2) with OPDIVO + chemo vs 11.1 mos (95% CI: 10.0–12.1) with chemo alone; HR=0.71 (95% CI: 0.61–0.83); P<0.0001. mOS in all comers was 13.8 mos (95% CI: 12.6–14.6) with OPDIVO + chemo vs 11.6 mos (95% CI: 10.9–12.5) with chemo alone (HR=0.80; 95% CI: 0.71–0.90: P=0.0002).1,2 IIChemo with placebo or other agents. ¶Based on median follow-up of 71.3 months (minimum 60.1 months) in Checkmate 649.2,3 #In Checkmate 648, based on a 13.0–month primary analysis, mOS in PD-L1 TC ≥1% was 15.4 mos (95% CI: 11.9–19.5) with OPDIVO + chemo vs 9.1 mos (95% CI: 7.7–10.0) with chemo alone; HR=0.54 (95% CI: 0.41–0.71); P<0.0001. mOS in all comers was 13.2 mos (95% CI: 11.1–15.7) with OPDIVO + chemo vs 10.7 mos (95% CI: 9.4–11.9) with chemo alone; (HR=0.74; 95% CI: 0.61–0.90; P=0.0021). At 4-year follow-up (minimum follow-up 45.1 months), mOS in PD-L1 TC ≥1% was 15.0 mos (95% CI: 11.9–18.7) with OPDIVO + chemo vs 9.1 mos (95% CI: 7.7–10.0) with chemo alone; HR=0.60 (95% CI: 0.47–0.77). mOS in all comers was 13.2 mos (95% CI: 11.1–15.7) with OPDIVO + chemo vs 10.7 mos (95% CI: 9.4–12.1) with chemo alone; (HR=0.77; 95% CI: 0.65–0.92).1,4
CHECKMATE 649
*OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.1
CHECKMATE 648
†OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).1
1L=first-line; CPS=combined positive score; EAC=esophageal adenocarcinoma; ESCC=esophageal squamous cell carcinoma; GC=gastric cancer; GEJC=gastroesophageal junction cancer; I-O=immuno-oncology; mOS=median overall survival; mos=months; mUGI=metastatic upper gastrointestinal; TC=tumor cell.
*Fluoropyrimidine- and platinum-containing chemotherapy.1 In Checkmate 649: OPDIVO + FOLFOX and OPDIVO + CapeOx; in Checkmate 648: OPDIVO + cisplatin and 5-FU.1
5-FU=5-fluorouracil; CapeOx=capecitabine and oxaliplatin.
CHECKMATE 649: IN PATIENTS WITH ADVANCED OR METASTATIC NON-HER2+ GASTRIC CANCER, GEJ, AND ESOPHAGEAL
ADENOCARCINOMAS
*mFOLFOX6 (leucovorin, fluorouracil, and oxaliplatin) regimen was given in Checkmate 649.1
†Assessed using blinded independent central review (BICR).1
‡Based on confirmed response.1
§All comers refers to all randomized patients in Checkmate 649.
CNS=central nervous system; CPS=combined positive score; ECOG PS=Eastern Cooperative Oncology Group Performance Status; FDA=US Food and Drug Administration; GEJ=gastroesophageal junction; HER2=human epidermal growth factor receptor 2; IHC=immunohistochemistry; IV=intravenous; ORR=overall response rate; OS=overall survival; PD-L1=programmed death-ligand 1; PFS=progression-free survival; q2w=every 2 weeks; q3w=every 3 weeks; q4w=every 4 weeks; ROW=rest of world; UGI=upper gastrointestinal.
LIMITATION: The 60-month follow-up analyses were not statistically powered and cannot detect differences between treatment arms.
Primary analysis (minimum follow-up 12.1 months): Secondary endpoints in the all comers† population (n=1581)1
Primary analysis: dual primary endpoints in the PD-Ll CPS ≥5 population (n=955)1
Secondary endpoint in the PD-L1 CPS ≥1 population (n=1296)1
Extended follow-up at 5 years2
*Vs chemotherapy alone.1
†All comers refers to all randomized patients in Checkmate 649.
‡FOLFOX or CapeOx.1
§Assessed using blinded independent central review (BICR).1
CI=confidence interval; HR=hazard ratio; mos=months; mOS=median OS; mPFS=median PFS.
Serious Adverse Reactions
In Checkmate 649, serious adverse reactions occurred in 52% of patients treated with OPDIVO in combination with chemotherapy (n=782). The most frequent serious adverse reactions reported in ≥2% of patients treated with OPDIVO in combination with chemotherapy were vomiting (3.7%), pneumonia (3.6%), anemia (3.6%), pyrexia (2.8%), diarrhea (2.7%), febrile neutropenia (2.6%), and pneumonitis (2.4%). Fatal adverse reactions occurred in 16 (2.0%) patients who were treated with OPDIVO in combination with chemotherapy; these included pneumonitis (4 patients), febrile neutropenia (2 patients), stroke (2 patients), gastrointestinal toxicity, intestinal mucositis, septic shock, pneumonia, infection, gastrointestinal bleeding, mesenteric vessel thrombosis, and disseminated intravascular coagulation.
Please see additional Important Safety Information below.
Primary analysis (12.1-month follow-up) in all comers1*†‡
*Assessed using the blind independent central review (BICR).1
†Based on confirmed response.1
‡All comers refers to all randomized patients in Checkmate 649.
§Secondary endpoint.5
∥FOLFOX or CapeOx.1
¶An exploratory endpoint.5
CR=complete response; ITT=intention to treat; mDOR=median duration of response; ORR=overall response rate; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors.
Common Adverse Reactions
In Checkmate 649, the most common adverse reactions (≥20%) in patients treated with OPDIVO in combination with chemotherapy (n=782) were peripheral neuropathy (53%), nausea (48%), fatigue (44%), diarrhea (39%), vomiting (31%), decreased appetite (29%), abdominal pain (27%), constipation (25%), and musculoskeletal pain (20%).
Please see additional Important Safety Information below.
Continue treatment until disease progression, unacceptable toxicity, or up to 2 years
*Fluoropyrimidine- and platinum-containing chemotherapy.1
†FOLFOX and CapeOx can be synchronized when used q2w and q3w, respectively.1
‡Based on the Checkmate 649 study design (see OPDIVO Full Prescribing Information for more information).1
§The OPDIVO 480 mg q4w dosing was included as an option in the Checkmate 649 study design; OPDIVO 480 mg q4w is not an approved dose for this indication (see OPDIVO Full Prescribing Information for more information).1
CHECKMATE 648: IN THE 1L TREATMENT OF ADULT PATIENTS WITH METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
*Checkmate 648 included a third arm: OPDIVO 3 mg/kg IV q2w + ipilimumab 1 mg/kg IV q6w; n=325. The trial was not designed to compare OPDIVO + chemotherapy to OPDIVO + ipilimumab. Please refer to the full U.S. Prescribing Information for further information.1,6
†OPDIVO 240 mg IV on Days 1 and 15 of a 4-week cycle.1
‡Fluorouracil 800 mg/m2/day IV on Days 1 through 5 (for 5 days) and cisplatin 80 mg/m2 IV on day 1 (of a 4-week cycle).1
§Patients could receive OPDIVO plus ipilimumab until disease progression, unacceptable toxicity, or up to 2 years.1
¶Assessed using blinded independent central review (BICR).1
#All comers refers to all randomized patients in Checkmate 648.1
ECOG PS=Eastern Cooperative Oncology Group Performance Status; IHC=immunohistochemistry; IV=intravenous; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; q2w=every 2 weeks; q4w=every 4 weeks; q6w=every 6 weeks.
LIMITATION: The 45-month follow-up analysis was not statistically powered and cannot detect differences between treatment arms.4,6
Dual primary endpoints in the PD-L1 TC ≥1% population (n=315)1
26% reduction in the risk of death with OPDIVO + chemotherapy‡ vs chemotherapy‡
alone in the all-comers† population in the primary analysis1
Secondary endpoint1
Extended follow-up at 45 months4
*Vs chemotherapy alone.1
†All comers refers to all randomized patients in Checkmate 648.
‡Fluorouracil and cisplatin.1
§Minimum follow-up 45.1 months.4
IIAssessed using blinded independent central review (BICR).1
CI=confidence interval; HR=hazard ratio; mOS=median overall survival; mPFS=median progression-free survival; NS=not significant.
Serious Adverse Reactions
In Checkmate 648, serious adverse reactions occurred in 62% of patients receiving OPDIVO in combination with chemotherapy (n=310). The most frequent serious adverse reactions reported in ≥2% of patients who received OPDIVO with chemotherapy were pneumonia (11%), dysphagia (7%), esophageal stenosis (2.9%), acute kidney injury (2.9%), and pyrexia (2.3%). Fatal adverse reactions occurred in 5 (1.6%) patients who received OPDIVO in combination with chemotherapy; these included pneumonitis, pneumatosis intestinalis, pneumonia, and acute kidney injury.
Please see additional Important Safety Information below.
Primary analysis in all comers1‡§II
*Fluorouracil and cisplatin.1
†Minimum follow-up 45.1 months.4
‡All comers refers to all randomized patients in Checkmate 648.
§Secondary endpoint.1
∥Assessed using blinded independent central review (BICR).1
¶An exploratory endpoint.6
CR=complete response; mDOR=median duration of response; PR=partial response.
Common Adverse Reactions
In Checkmate 648, the most common adverse reactions (≥20%) in patients treated with OPDIVO in combination with chemotherapy (n=310) were nausea (65%), decreased appetite (51%), fatigue (47%), constipation (44%), stomatitis (44%), diarrhea (29%), and vomiting (23%).
Please see additional Important Safety Information below.
Continue treatment until disease progression, unacceptable toxicity, or up to 2 years for OPDIVO
Continue treatment until disease progression, or unacceptable toxicity for chemotherapy
Refer to respective Prescribing Information for each therapeutic agent administered in combination with OPDIVO for the recommended dosage and administration information, as appropriate1
Administer OPDIVO first, followed by fluoropyrimidine- and platinum-containing chemotherapy on the same day1
In the Checkmate 648 study design,1 in patients with mESCC who received OPDIVO in combination with chemotherapy and in whom either fluorouracil and/or cisplatin were discontinued, other components of the treatment regimen were allowed to be continued1
*Based on the Checkmate 648 trial design (see OPDIVO Full Prescribing Information for more information).1
GC=gastric cancer; mESCC=metastatic esophageal squamous cell carcinoma.
View a selected safety profile of adverse reactions seen in clinical trials.
Find dosing information to get patients started on therapy.
Learn more about other gastroesophageal indications across adjuvant and 1L metastatic settings.
References: